



## (51) International Patent Classification:

**C07C 271/34** (2006.01) **A61K 31/27** (2006.01)  
**C07C 249/06** (2006.01) **A61K 31/215** (2006.01)  
**C07D 261/18** (2006.01) **A61P 35/00** (2006.01)  
**C07D 277/32** (2006.01) **A61K 31/381** (2006.01)  
**C07D 309/08** (2006.01) **A61K 31/4192** (2006.01)  
**C07D 333/38** (2006.01) **A61K 31/42** (2006.01)  
**C07D 401/04** (2006.01) **A61K 31/426** (2006.01)  
**C07D 295/21** (2006.01)

## (21) International Application Number:

PCT/DK2011/000154

## (22) International Filing Date:

22 December 2011 (22.12.2011)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

|            |                                |    |
|------------|--------------------------------|----|
| 61/426,378 | 22 December 2010 (22.12.2010)  | US |
| 61/448,350 | 2 March 2011 (02.03.2011)      | US |
| 61/534,055 | 13 September 2011 (13.09.2011) | US |

(71) Applicant (for all designated States except US): **LEO PHARMA A/S** [DK/DK]; Industriparken 55, DK-2750 Ballerup (DK).

## (72) Inventors; and


(75) Inventors/Applicants (for US only): **GRUE-SØRENSEN, Gunnar** [DK/DK]; c/o Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **LIANG, Xifu** [CN/DK]; c/o Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **HÖGBERG, Thomas** [SE/DK]; c/o Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **MÅNS-SON, Kristoffer** [SE/DK]; c/o Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **VEDSØ, Per** [DK/DK]; c/o Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK). **VIFIAN, Thomas** [CH/DK]; c/o Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK).

(74) Agent: **HORNEMAN, Anne Marie**; Patent Counsel, Leo Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES



(57) Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R<sup>7</sup>; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R<sup>8</sup>; or R is X wherein X is -NR<sup>11</sup>R<sup>12</sup>; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))